-+ 0.00%
-+ 0.00%
-+ 0.00%

Revolution Medicines alleges Erasca ERAS-0015 infringes patent, misuses trade secrets

PUBT·04/27/2026 12:34:40
Listen to the news
Revolution Medicines alleges Erasca ERAS-0015 infringes patent, misuses trade secrets
  • Revolution Medicines counsel sent Erasca letter on April 24, 2026 alleging ERAS-0015 infringes U.S. Patent No. 12,409,225 under doctrine of equivalents.
  • Letter also alleged trade secret misappropriation tied to a patent relating to ERAS-0015, with Erasca accused of liability as a licensee.
  • RevMed demanded Erasca stop making or selling ERAS-0015 in U.S. outside Hatch-Waxman safe harbor.
  • Erasca said allegations lack merit.
  • Company plans to contest claims vigorously.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-179214), on April 27, 2026, and is solely responsible for the information contained therein.